



This is a repository copy of *Phototoxicity of cyclometallated Ir(III) complexes bearing a thio-bis-benzimidazole ligand, and its monodentate analogue, as potential PDT photosensitisers in cancer cell killing.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/208823/>

Version: Published Version

Article:

Martínez-Alonso, M. orcid.org/0000-0002-0931-5274, Jones, C.G. orcid.org/0000-0003-2958-8322, Shipp, J.D. orcid.org/0000-0002-0452-8895 et al. (3 more authors) (2024) Phototoxicity of cyclometallated Ir(III) complexes bearing a thio-bis-benzimidazole ligand, and its monodentate analogue, as potential PDT photosensitisers in cancer cell killing. JBIC Journal of Biological Inorganic Chemistry. ISSN 0949-8257

<https://doi.org/10.1007/s00775-023-02031-z>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>



Phototoxicity of cyclometallated Ir(III) complexes bearing a thio-bis-benzimidazole ligand, and its monodentate analogue, as potential PDT photosensitisers in cancer cell killing

Marta Martínez-Alonso^{1,2} · Callum G. Jones^{1,2} · James D. Shipp¹ · Dimitri Chekulaev¹ · Helen E. Bryant² · Julia A. Weinstein¹

Received: 31 July 2023 / Accepted: 18 October 2023
© The Author(s) 2024

Abstract

Two novel cyclometallated iridium(III) complexes have been prepared with one bidentate or two monodentate imidazole-based ligands, **1** and **2**, respectively. The complexes showed intense emission with long lifetimes of the excited state. Femtosecond transient absorption experiments established the nature of the lowest excited state as ³IL state. Singlet oxygen generation with good yields (40% for **1** and 82% for **2**) was established by detecting ¹O₂ directly, through its emission at 1270 nm. Photostability studies were also performed to assess the viability of the complexes as photosensitizers (PS) for photodynamic therapy (PDT). Complex **1** was selected as a good candidate to investigate light-activated killing of cells, whilst complex **2** was found to be toxic in the dark and unstable under light. Complex **1** demonstrated high phototoxicity indexes (PI) in the visible region, PI > 250 after irradiation at 405 nm and PI > 150 at 455 nm, in EJ bladder cancer cells.

Keywords PDT · Anticancer drugs · Iridium · Phototoxicity

Introduction

Cancer is one of the most malignant diseases in the world. In 2016, it was among the 10 most frequent causes of death, especially in upper-middle and high-income countries [1]. Although new therapies are emerging, surgery and chemotherapy are still the most frequently used techniques to treat cancer. Metal-containing anticancer drugs such as cisplatin and its derivatives are among the best anticancer drugs up to date. Nevertheless, they have lots of side effects in patients because they usually target all proliferative tissues [2]. In this context, Photodynamic Therapy (PDT), widely used to treat actinic keratosis [3, 4], acne [5], age-related

macular degeneration [6], barrets oesophagus [7], viral warts [8], periodontal disease [9], or infectious diseases [10], is gaining more and more attention, for its localised effects. PDT requires a photosensitizer (PS), a source of light and molecular oxygen. When a PS is irradiated with light of a specific wavelength, PS molecules absorb light and populate a singlet excited state, which in turn populates a triplet excited state, ³PS, in the process called “intersystem crossing”. Afterwards, two pathways of ³PS interaction with oxygen are possible. (a) Type I or electron transfer (eT): the ³PS transfers an electron to molecular oxygen (³O₂) releasing ROS species. (b) Type II or energy transfer (ET): the ³PS transfers its energy to molecular oxygen (³O₂), leading to population of singlet oxygen (¹O₂). Both ROS and (¹O₂) are reactive species able to kill cells [11]. As ROS (¹O₂) are only produced at local sites of irradiation, PDT is more specific to tumour cells than most existing chemotherapies. To this end, many transition metal complexes are being discovered as efficient photosensitisers, owing to their efficient absorption of visible light, followed by ultrafast population of a triplet excited state – facilitated by the presence of a heavy atom, the metal centre – which in turn ensures long excited state lifetime (hundreds of nanoseconds or longer), and the high yields of ROS. For example, a photo-active Ru(II) complex,

✉ Helen E. Bryant
h.bryant@sheffield.ac.uk

✉ Julia A. Weinstein
julia.weinstein@sheffield.ac.uk

¹ Department of Chemistry, University of Sheffield, Sheffield S3 7HF, UK

² Department of Oncology and Metabolism, Medical School, The University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK

TLD-1433, prepared by McFarland and co-workers is in phase II clinical trials [12–14].

Amongst transition metal complexes, many Ir(III) complexes have been reported as promising photosensitizers for PDT [15–18], and reviewed in, for example, [19]. Our previous study reported phototoxic properties of two cyclometallated Ir(III) complexes bearing bisbenzimidazole or its methylated analogue, N-methylated bisbenzimidazole. The complex with bisbenzimidazole, carrying an -NH group, displayed low dark toxicity and a high phototoxicity index (PI) at 405 nm ($LD_{50\text{dark}} > 100 \mu\text{M}$, $PI > 333$), whereas its N-methylated analogue was highly toxic in the dark and showed low PI ($LD_{50\text{dark}} = 6.2 \mu\text{M}$, $PI = 12.4$) [20].

Usually, such complexes have a general formula of $[\text{Ir}(\text{N}^{\wedge}\text{C})_2(\text{NN})]$, with two cyclometallating, and one bidentate diimine ligand. N-monodentate ligands have not been extensively explored in complexes for PDT. The limited examples reported include imidazole-based Ir(III) complexes as PDT and PACT (photoactivated chemotherapy) agents with PI values up to 61 [21], and imidazole complexes of Pt(II), Ir(III) and Ru(II) in reductive media containing glutathione (GSH)[22] which undergo photo-triggered release of the ligands.

In this work, we present the photodynamic effect of two Ir(III) imidazole-based photosensitizers, one with a chelating diimine ligand and the other with two N-monodentate ligands. The complexes were designed with the aim of shifting the absorption towards the more tissue penetrating red region of the spectrum but maintaining the imidazole -NH functionality, reported to be a relevant scaffold in PDT [20, 23–25]. With this goal in mind, we prepared a sulfur-containing analogue of bis-benzimidazole, 2-(2'-benzothiazolyl)-benzimidazole (btzbimH, Fig. 1), and combined this diimine ligand with 2-(2-thienyl)pyridine (thpy) as the cyclometallating ligand. One of the low-lying excited states in this type of complexes is intraligand charge-transfer state to the pyridine from either phenyl(–) or thienyl(–), components of

the N[^]C ligands. Thpy contains a more electron-donating thienyl group than the phenyl group in the phenyl-pyridine (ppy), leading to complexes bearing thpy possessing a lower-energy ILCT state, shifting absorption maximum to the more favourable for the PDT red region of the spectrum [26–28]. Since the -NH moiety on the ancillary ligand(s) could modulate the total charge of the complex, through the acid–base equilibrium, affecting the cellular uptake and localization of the complex [23, 25, 29], the effect of pH on photophysical properties of the complexes was investigated. The photophysical properties, chemical and photochemical stability, and the propensity of the complexes to act as photosensitizers were investigated and the influence of the monodentate vs. bidentate N[^]N ligands established. Furthermore, complex $[\text{Ir}(\text{thpy})_2(\text{btzbim})]^+$ (**1**) was shown to be a promising PDT agent in EJ cells (bladder cancer cells) under both 405 nm and 455 nm irradiation, with appreciable phototoxicity indices.

Results and discussion


Synthesis of the complexes

The starting dimer $[\text{Ir}(\mu\text{-Cl})_2(\text{thpy})_2]$, was prepared following the Nonoyama protocol [30]. $\text{IrCl}_3 \cdot x\text{H}_2\text{O}$ was reacted with the ligand 2-(2-Thienyl)pyridine (thpy) to yield a chloride-bridge binuclear complex. Then, the dimer was refluxed with the corresponding ligands in a dichloromethane/methanol mixture for 24 h to yield complexes **1** and **2** (Scheme 1 and Experimental section) as the racemic mixture.


The ligand 2-(2'-benzothiazolyl)-benzimidazole (btzbimH) was synthesized according to a literature procedure[31] using a microwave reactor (see Experimental section).

A complete characterization was performed by NMR (1D ¹H- and ¹³C-NMR, and 2D NMR methods, COSY and

Fig. 1 Asymmetric unit of complex **1** showing the optical isomers Λ and Δ , solved by X-ray diffraction. Red arrows indicate the lack of the hydrogen in what would be the NH group



Scheme 1. Synthetic scheme of complexes **1** and **2**. Note: All the compounds were prepared as the racemic mixtures of Δ and Λ isomers. The drawings show only one of them for illustrative purposes. Likewise, only one variant of the stereochemistry is shown for the dimeric complex



HSQC, Figure S1, S2, S4, S5) and ESI-MS/TOFMS (Figs. S3, S6). As expected, the ^1H NMR spectrum of complex **1** showed asymmetry, whereas the NMR spectrum of complex **2** exhibited a symmetric complex. Complex **2** slightly decomposed during the recording of the NMR (Fig. S4), resulting in the appearance of a set of peaks corresponding to an asymmetric product. In order to explain this phenomenon, the lability of the monodentate ligands as well as the stability of the complexes have been investigated and are described below. The MS spectra displayed the typical isotopic distribution pattern of Iridium complexes. Interestingly, the MS spectrum of **2** showed three peaks, assigned to the exact mass main peak $[\text{M}]^+$, the loss of one of the monodentate MeIm ligands $[\text{M}-\text{MeIm}]^+$, and the replacement of the MeIm ligand by a molecule of acetonitrile (used as the solvent) $[\text{M}-\text{MeIm} + \text{CH}_3\text{CN}]^+$.

The single crystal X-ray structure of **1** was determined, using single crystals formed by slow evaporation of the solvent from solution of **1** in dichloromethane (Fig. 1). The asymmetric unit contains two complexes corresponding to the two enantiomers, Λ and Δ , and three CH_2Cl_2 molecules. The structure shows off-centred π - π stacking interactions between the btzbiH ligands. The connection between both isomers is reinforced by $\text{CH}\cdots\pi$ interactions (see Fig. S7; Table S1–S4), also involving the thienyl ring. Unexpectedly, the complex was found to be neutral, since neither a counterion nor electronic density in the nitrogen of the imidazole ring (see red arrows in Fig. 1) was found. Accordingly, the ^1H NMR spectrum of **1** does not show any peak for the NH. Another evidence of the lack of the H-atom on the imidazole is that, in both isomers, the N atom is participating in weak hydrogen bond interactions as an acceptor ($\text{C}-\text{H}\cdots\text{N}$,


see Table S5)[32]: in the Λ isomer, H-bonding occurs with a CH_2Cl_2 molecule, and in the Δ isomer, with a hydrogen atom of the aromatic ring of another Δ isomer.

The complex presents a distorted octahedral geometry, with the N-donor atoms of the two cyclometallated ligands being in *trans* position to one another. The Ir-C and Ir-N bond lengths are in the usual range reported for similar complexes [27, 33–35], with the Ir-N distances (2.02–2.07 Å) in the thpy ligand longer than Ir-C ones (1.96–2.02 Å), due to the *trans* effect. The bite angles for the cyclometallating ligands are smaller than 90° , evidencing the distorted geometry. Moreover, for the btzbiH ligand, the bite angles (75° and 77°) are considerably smaller than for the cyclometallated ones (79 – 80.5°)[33, 36, 37] The btzbiH ligand presents a twisted non-planar geometry, with angles between the planes of the benzimidazole and benzothiazole being 12.68° for the Λ isomer and 7.29° for the Δ isomer.

Photophysical properties

The photophysical properties of the complexes in CH_2Cl_2 were investigated under air and under argon atmosphere (Figs. S8 and S9). Both **1** and **2** exhibit strong absorption bands at 250–350 nm, due to spin-allowed $^1\pi-\pi^*$ ^1LC transitions. The low energy bands, 350–450 nm, correspond to spin-allowed $^1\text{MLCT}$, $^1\text{LLCT}$ transitions, whereas the weak absorption tails above 450 nm would comprise spin-forbidden $^3\text{MLCT}$, $^3\text{LLCT}$ and $^3\pi-\pi^*$ ^3LC transitions (Fig. 2A). Upon excitation of solution of **1** or **2** at room temperature, the orange-red emission was observed (Fig. 2B). The spectra have pronounced vibronic structure with the two main peaks being the same for both

Fig. 2 AUV–Vis absorption and **B** normalized emission intensity spectra of complexes **1** (10^{-5} M, $\lambda_{\text{exc}} = 440$ nm) and **2** (2×10^{-5} M, $\lambda_{\text{exc}} = 432$ nm) under argon in CH_2Cl_2 at r.t



complexes **1** (546 and 593 nm) and **2** (546 and 590 nm), indicating emission with a considerable ^3LC character. In addition, the spectrum of **2** (including the shoulder at 640 nm) has the same shape to that reported for $[\text{Ir}(\text{thpy})_2(1,1'\text{-dimethyl-}2,2'\text{-biimidazole})]\text{PF}_6$, [34]. These observations point out a main contribution from a ^3LC transition involving the thpy ligands, for **2**, whereas for **1** an additional contribution of emission from a CT state may play a role. The emission quantum yields (measured in air) for **1** and **2** in CH_2Cl_2 (0.029 and 0.016, respectively) are relatively small, and the characteristic emission lifetime is approximately 200 ns for both complexes. The excited state lifetimes in deoxygenated solution are considerably longer than in aerated solutions, with *ca.* 2 μs for **2**, and a somewhat shorter, *ca.* 800 ns, for **1**, which could also be due to a mixed CT/LC nature of the emissive state in **1**. Table 1 gathers the photophysical properties of complexes **1** and **2** under air and argon.

Stability and photostability of the complexes

The photostability of the complexes was tested in water (1 or 2% DMSO), under irradiation with a 405 nm diode (20 mW) with the process followed by UV–vis absorption spectroscopy. Complex **1** was stable after 90 min of irradiation (Fig. S10), the slight changes observed in the spectra were possibly due to precipitation. However, the absorption spectrum of complex **2** showed pronounced changes upon irradiation, with two isosbestic points (Fig. 3). Moreover, the emission of **2** completely disappeared after 150 min of irradiation with 405 nm light (Figure S11), suggesting the release of some of the ligands, as reported by Wu et al. [21]. The same changes, although occurring slower, were also detected in a sample exposed to ambient light (Figure S12). A time-dependent $^1\text{H-NMR}$ experiment was conducted in $\text{DMSO-d}_6/\text{D}_2\text{O}$ (70/30) to try to work out the molecular changes (Figs. S13–S14). Unexpectedly, the changes in the NMR spectra in this solvent mixture occur much slower than in water (monitored by UV–vis spectroscopy). The NMR data confirm that one of the MeIm monodentate ligands

Table 1 Photophysical properties of **1** (10^{-5} M) and **2** (2×10^{-5} M) in CH_2Cl_2

Complex	λ_{exc} [nm] (ϵ [$\text{M}^{-1} \text{cm}^{-1}$])	λ_{em} [nm] ^a	Φ_{em} ^b	Φ_{s} ($^1\text{O}_2$) ^c	τ [ns]	k_{r} [$\times 10^{-5} \text{s}^{-1}$]	k_{nr} [$\times 10^{-5} \text{s}^{-1}$]
1-Air	279 (27,778), 348 (23,795), 362 (23,727), 394 (sh, 18,282), 440 (5527)	λ_{440} 544, 593	0.029 ± 0.002	0.40	230	1.3 ± 0.1	45 ± 1
1-Ar	283 (27,851), 346 (24,768), 363 (24,919), 391 (sh, 17,759), 440 (9487)	λ_{440} 545, 590	–	–	800 (20%), 300 (80%) ^d	–	–
2-Air	282 (23,124), 419 (4753), 512 (1275)	λ_{432} 546, 591	0.016 ± 0.001	0.82	196	0.82 ± 0.05	50 ± 1
2-Ar	283 (24,890), 418 (4528), 512 (1089)	λ_{432} 546, 590	–	–	1980	–	–


^aExcitation wavelength as stated

^bRelative to $[\text{Ru}(\text{bpy})_3]^{2+}$ Φ_{em} in CH_2Cl_2 (0.029 [38])

^cRelative to perinaphthenone ($\Phi_{\text{s}} = 1$)

^dWe note the biexponential decay of emission of **1** under Ar atmosphere. It is possible that there is an emission from two triplet states, a primarily ILCT one, and a primarily MLCT one. There was no obvious concentration dependence. The excitation spectra recorded at different emission wavelengths follow the absorption spectra (see SI) hence emission originates from the parent compound

Fig. 3 Time-dependent UV–vis spectra of complex **2** in water (2% DMSO) after irradiation (405 nm, 20 mW). Inset: kinetic traces recorded at 382 nm (growth of absorbance of the product) and 425 nm (prevailing absorbance by starting material)



was released and that the main species responsible for the changes were water molecules. Thus, we propose a substitution mechanism (see Scheme 2), in which the imidazole is replaced by a water (or another solvent) molecule.

In order to check the effect of light, we performed the same experiment for **2** in dark conditions in water, PBS and in clear cell medium. Figure S15 displays the effect of the different solvents on the absorption spectra, with large changes observed in aqueous solution, but negligible changes occurring in cell media. Thus, complex **2** is not stable in water or PBS, but it is stable in cell media under irradiation.


Protonation/deprotonation process


The pK_a for **1** was 6.97 in a PBS buffered solution (Figure S16). This means complex **1** will be mainly present in the deprotonated, neutral form in the cell culture, whose pH is 7.4. The protonated, charged form will dominate in acidic environments, such as tumour cells (pH 6.5–6.8) or lysosomes (pH 4.5–5.5) [23]. For a similar complex [Ir(ppy)₂(pybz)] (where ppy = 2-(2-phenylpyridine) and

pybz = 2-(2-pyridyl)benzimidazole), the emission spectra of deprotonated and protonated forms in solution are different. However, the emission emanated from cells incubated with either form for 5 min (for [Ir(ppy)₂(pybz)], $pK_a = 6.6$, intracellular pH ~ 7.4), indicating that the uptake was not affected by charge and (de)protonation [39], and that only one form (deprotonated) is present inside the cells.

For complex **2**, the accurate measurement of pK_a was problematic due to its instability. However, a fast measurement allowed us to estimate two pK_a values: $pK_{a1} \sim 4.13$ and $pK_{a2} \sim 7.20$ (Scheme 3 and S17), each of these values were lower than the one for the free 2-methylimidazole ($pK_a = 7.86$ [40]), as can be expected due to coordination to the metal. If one assigns the two pK_a values to the consecutive deprotonation of the NH of the two ligands, one can correlate the decomposition of **2** with the pH. In distilled water with pH 5.8, one of the imidazoles would be in the deprotonated form, whereas the other one would be protonated and prone to uncaging. In cell media at pH 7.4, both imidazoles would be deprotonated and it will probably be more difficult to release the ligand. This hypothesis could also explain the

Scheme 2. Proposed scheme for the photo-uncaging of the imidazole ligand and its replacement with a water molecule in complex **2**





Scheme 3. Protonation/deprotonation process scheme of complex **2**

observed slower uncaging process in the NMR experiments performed in D_2O which is less acidic than H_2O .

Singlet oxygen sensitization

The decrease in the emission intensity and lifetime in presence of oxygen pointed out to molecular oxygen as a quencher of the emissive state, which typically result in production of singlet oxygen. The yield of singlet oxygen production in CH_3CN solutions was determined by direct detection of its emission at 1270 nm, using perinaphthone as the reference ($\Phi_s = 1$ in CH_3CN [41]). Singlet oxygen quantum yields were high, 0.40 for **1** and 0.82 for **2**, with the lower value for **1** correlating well with its shorter excited state lifetime, and a smaller estimated rate constant of quenching by oxygen (Table 1).

Cyclic voltammetry

The electrochemical behaviour of **1** and **2** was investigated by cyclic voltammetry in CH_2Cl_2 (Fig. 4 and Table 2 with a glassy carbon working electrode, a platinum wire counter electrode and $Ag/AgCl$ (0.1 mol dm^{-3}) reference electrode. The redox couple Fc/Fc^+ was used as the internal reference. The main oxidation peaks at +0.80 V (**1**) and +0.67 V (**2**) are assigned to the oxidation of the Ir-thpy environment (Ir^{III} to Ir^{IV}). The more positive value for **1** is the consequence of the stronger LFSE (ligand field stabilization energy) for the bidentate chelate ligand than for the two monodentate ligands in **2**. The additional, small, reversible oxidation process observed for **2** at +0.39 V corresponds to the oxidation of the Cl^- anion. The lack of the same oxidation peak in **1**, also confirms the absence of a chloride counterion in the complex and indirectly, its neutral nature. The reduction processes (−1.61 V for **1** and −2.10 V for **2**) are irreversible and they are usually ascribed to the ancillary ligands. The more negative value for **2** might be caused by the introduction of electron-donating methyl groups.




Fig. 4 Cyclic voltammograms of complexes **1** and **2** in CH_2Cl_2 solution (10^{-3} M), using 0.4 M $[NBu_4][PF_6]$ as supporting electrolyte. Scan rate: 100 mV/s . Potential vs. Fc/Fc^+

Table 2 Electrochemical properties (vs. Fc/Fc^+) of **1** and **2** in CH_2Cl_2 solution (10^{-3} M), using 0.4 M $[NBu_4][PF_6]$ as supporting electrolyte. Scan rate: 100 mV/s

Compound	$E_{1/2}^{ox}$	$E_{1/2}^{red}$	$\Delta E_{1/2}$
1	+0.80	−1.61	2.41
2	+0.39, +0.67	−2.10	2.77

Transient absorption spectroscopy

The transient absorption spectra obtained after 400 nm, 40-fs excitation of the solution of **1** in DCM at r.t., on the time scale 0–8 ns, are shown in Fig. 5. The data were fitted using Glotaran global analysis routine with a sequential 3-exponential model, with the time-constants of 1.32 ps, 14 ps, and an additional “infinity” value to account for the final,




Fig. 5 Transient absorption data for **1** in aerated DCM, excitation 400 nm, 40 fs. Top: 2D-representation of the complete dataset; bottom—spectra at selected time delays after the excitation

emissive state (the latter was arbitrary fixed as 225 ns, to match emission lifetime). The spectra associated with each time constant are shown in the SI (decay-associated spectra). The transient absorption spectra at early times show slight vibrational progression (455 nm, 495 nm, and 550 nm) typical of intraligand excited states. These features become more pronounced, with the time-constant of 1.32 ps, whilst a lower-energy broad absorbance at ca. 640 nm (where one might expect the diimine radical-anion absorbance) decreases in intensity. Further sharpening of the spectral features occur with 14 ps timeconstant (perhaps due to vibrational cooling), after which the spectral shape remains unchanged on the timescale of the experiment (8 ns).

Cytotoxicity and phototoxicity

The cytotoxicity of the complexes in the dark and upon light irradiation was evaluated in bladder cancer EJ cells after 2 h incubation. Compound **2** was found to be cytotoxic in the dark ($LD_{50} = 5.77 \mu\text{M}$), whereas **1** was not cytotoxic within the limits of testing ($> 200 \mu\text{M}$, solubility limit) (Fig. 6, Table 3). Therefore, **1** was selected for further studies. After




Fig. 6 Dark toxicity of **1** and **2** in EJ cells after 2 h incubation. Data are normalised to DMSO alone control, mean and SEM of 3 independent repeats each performed in triplicate is shown

Table 3 Cytotoxicity and phototoxicity of **1** and **2** in EJ cells after 2 h

Compound	Dark	405 nm		455 nm	
	LD_{50} dark (μM)	LD_{50} light (μM)	PI	LD_{50} light (μM)	PI
1	> 200	0.79	> 250	1.33	> 150
2	5.77	—	—	—	—




Fig. 7 Dark and light ($\lambda_{\text{exc}} = 405 \text{ nm}$, 20 mW/cm^2 , 3 min and $\lambda_{\text{exc}} = 455 \text{ nm}$, 30 mW/cm^2 , 3 min) toxicity of **1**. Data are normalised to DMSO alone control, mean and SEM of 3 independent repeats each performed in triplicate is shown

2 h of incubation, cells were irradiated at 405 nm or 455 nm for 3 min and survival analysed by clonogenic assay. At 405 nm the LD_{50} value for **1** was 0.79, resulting in a high PI value > 250 (Fig. 7, Table 3) compared to other Ir(III) similar biscyclometallated complexes [42, 43]. When irradiated at 455 nm, the LD_{50} and PI values decreased ($LD_{50} = 1.33$

PI > 150,) according to the lower absorption at higher wavelengths. The high toxicity of **2** in the dark is consistent with the high dark toxicity observed by Gao and co-workers for a similar complex. This could be explained as the effect caused by rapid replacement of one of the imidazoles by a glutathione molecule in cellular media [22].

Cellular uptake and localization

The strong emission of the Ir(III) complexes offers a useful tool for imaging, allowing one to follow the uptake process

and determine intra-cellular localization of the complexes, which can provide insights into the cell death mechanism. To investigate cellular uptake, dose and time-dependent imaging experiments were performed in EJ cells. For the dose experiment, cells were exposed to increasing concentrations of **1** (0, 10, 30 μM) for 2 h. Cytoplasmic localisation could be clearly seen in Fig. 8 at 10 μM , the intensity of emission (and hence the uptake) was seen to increase when the cells were incubated with a 30 μM solution of **1**.

Initial observations of the sub-cellular localisation of **1** suggest a mitochondrial like location. Co-localisation




Fig. 8 Cellular internalization of complex **1** in EJ cells at different concentrations (0, 10 and 30 μM) after 2 h

experiments were therefore performed in EJ cells using immunofluorescent staining for cytochrome c oxidase and utilising the phosphorescence of **1** (Fig. 9). The Pearson's correlation coefficient (PCC) displays a moderate correlation with a mean value of 0.75. The internalization of **1** in mitochondria could explain the toxicity of the compound after light activation, especially as mitochondria are crucial regulators of the apoptotic pathway.[44, 45]. However, further investigation is needed to examine the location of the portion of **1** that does not-colocalise with mitochondria.

Experimental part

Synthesis of the complexes

[Ir(thpy)₂(btzbim)]Cl (1). In a 100 mL round-bottomed flask, the precursor [Ir(μ -Cl)(thpy)₂] (39.4 mg, 0.036 mmol) along with the ligand 2-(2'-benzothiazolyl)benzimidazole (19.2 mg, 0.076 mmol) were dissolved in a methanol/dichloromethane mixture (1:1, 10 mL) under argon. The orange mixture was refluxed for 24 h. After this time, the yellowish clear solution was concentrated, and hexane was added to precipitate a yellow solid. The suspension was cooled down in the fridge for 30 min to help in the precipitation process. The crude solid was filtered off and washed with hexane twice. The yellow solid was dried under vacuum. Yield: 24 mg (0.032 mmol, 44%). ¹H NMR (400 MHz, Chloroform-*d*, 25 °C) δ 7.90 (d, *J* = 7.9 Hz, 1H), 7.78 (d, *J* = 8.2 Hz, 1H), 7.63 (d, *J* = 5.6 Hz, 1H), 7.52–7.41 (m, 6H), 7.39 (d, *J* = 4.6 Hz, 1H), 7.35 (t, *J* = 7.7 Hz, 1H), 7.20 (t, *J* = 7.8 Hz, 1H), 7.12 (t, *J* = 7.5 Hz, 1H), 6.89 (t, *J* = 7.6 Hz, 1H), 6.79 (d, *J* = 8.3 Hz, 1H), 6.63–6.54 (m, 2H), 6.48 (d, *J* = 4.8 Hz, 1H), 6.35 (d, *J* = 4.8 Hz, 1H), 6.13 (d, *J* = 8.3 Hz, 1H) ppm. ¹³C NMR (101 MHz, Chloroform-*d*, 25 °C) δ 165.7 (s, 1C), 165.1 (s, 1C), 164.7 (s, 1C), 164.1 (s, 1C), 150.4 (s, 1C), 137.5 (s, 2C), 137.2 (s, 1C), 132.4 (s, 1C), 131.5 (s, 1C),

129.3 (s, 1C), 128.5 (s, 1C), 127.6 (s, 1C), 125.9 (s, 1C), 125.8 (s, 1C), 122.9 (s, 1C), 122.8 (s, 1C), 121.2 (s, 1C), 119.6 (s, 2C), 117.7 (s, 1C), 117.4 (s, 1C), 116.0 (s, 1C) ppm. ESI+ (*m/z*) = 764.1 [M + H]⁺.

[Ir(thpy)₂(MeIm)₂]Cl (2). In a 100 mL round-bottomed flask, the precursor [Ir(μ -Cl)(thpy)₂] (100 mg, 0.091 mmol) along with the ligand 2-methyl imidazole (68 mg, 0.83 mmol) were dissolved in a methanol/dichloromethane mixture (1:1, 20 mL) under argon. The orange slurry mixture was refluxed for 24 h. After this time, the orangish clear solution was concentrated and diethyl ether was added to precipitate a yellow solid. The suspension was cooled down in the fridge overnight to help in the precipitation process. The crude solid was filtered off and washed with hexane twice. The yellow solid was dried under vacuum. Yield: 75 mg (0.105 mmol, 58%). ¹H NMR (400 MHz, DMSO-*d*₆, 25 °C) δ 12.49 (bs, 2H, H^{NH}), 8.69 (bs, 2H, H⁹), 7.81 (t, *J* = 7.5 Hz, 2H, H⁷), 7.59 (d, *J* = 8.2 Hz, 2H, H⁶), 7.36 (d, *J* = 4.7 Hz, 2H, H²), 7.16 (ddd, *J* = 7.4, 5.8, 1.5 Hz, 2H, H⁸), 7.07 (t, *J* = 1.9 Hz, 2H, H^b), 6.64 (bs, 2H, H^a), 6.08 (d, *J* = 4.7 Hz, 2H, H³), 1.93 (s, 6H, H^d) ppm. ¹³C NMR (101 MHz, DMSO-*d*₆, 25 °C) δ 189.1 (s, 2C, C¹), 163.9 (s, 2C), 151.6 (s, 2C), 138.8 (s, 2C, C⁷), 135.4 (s, 2C), 128.7 (s, 2C, C²), 119.8 (s, 2C), 117.4 (s, 2C, C⁶), 116.9 (s, 2C, C^b), 13.8 (s, 2C, C^d) ppm. ESI+ (*m/z*) = 595 [M-MeIm]⁺, 636 [M-MeIm + CH₃CN]⁺, 677 [M]⁺.

Materials and methods

IrCl₃·xH₂O was purchased from Johnson&Mattey and used as received. 2-(2-Thienyl)pyridine and 2-Methylimidazole were purchased from Sigma-Aldrich. Solvents were distilled and dried prior use. All the reactions were carried out under a dry and oxygen free argon atmosphere, using the Schlenk techniques, unless otherwise stated. Deuterated solvents were purchased from Eurisotop and used as received. NMR




Fig. 9 Sub-cellular localisation of complex **1** in EJ cells after 2 h incubation

spectra were recorded in a Bruker AVIIIHD 400 MHz spectrometer equipped with a 5 mm BBFO SmartProbe. ^1H and $^{13}\text{C}\{^1\text{H}\}$ spectra were referenced with the solvent residual peak. Chemical shift values are reported in ppm and coupling constants (J) in hertz.

Mass spectra were recorded in an Agilent Technologies 6530 Accurate Mass LC–MS QToF.

Stock solutions of complexes **1** and **2** were made up in DMSO and stored at $-20\text{ }^\circ\text{C}$.

Photophysical characterization

UV–vis absorption spectra in solution were recorded in an Agilent Varian Cary 50 or Agilent Varian Cary 5000 spectrometer using quartz cuvettes of 1 cm pathlength. Luminescence spectra were recorded in a Horiba Jobin Yvon Fluoromax-4 spectrofluorometer. Lifetimes were determined by time-correlated single photon counting (TCSPC) method, using Edinburgh Instrument Mini-tau spectrometer and following excitation with a pulsed laser diode at 405 nm, 75 ps. Lifetime values were determined through exponential fitting of the collected data. Quantum yields were determined by the indirect method, using $[\text{Ru}(\text{bpy})_3]\text{Cl}_2$ as the standard (0.029 in aerated acetonitrile) [38]. Absorption and emission spectra (at least 6 points) were recorded for increasing concentrations of the samples. The linear fitting from the integrated emission intensity vs. absorption graph, provided the gradient data from the slope. Finally, the quantum yield was calculated using the next equation,

$$\Phi_X = \Phi_{ST} \left(\frac{\text{Grad}_X}{\text{Grad}_{ST}} \right) \left(\frac{\eta_{ST}^2}{\eta_X^2} \right)$$

where X stands for the complex and ST for the reference or standard, Φ for the quantum yield, Grad for the gradient and η for the refraction index of the solvent. If the solvent of the compound and the reference is the same, the equation is simplified. Quartz cuvettes modified with a young connection tap of 1 cm pathlength were used for deaerated measurements under argon, after three freeze–pump–thaw cycles. pH measurements were performed on a Hanna Instruments 123 Microprocessor pH meter, in a pH range from 2 to 12, using HCl or NaOH solutions to adjust pH.

(Photo)stability measurements

Stability measurements were performed in aqueous solutions with 2% of DMSO (10^{-5} M for **1** and $2 \times 10^{-5}\text{ M}$ for **2**) in the dark and after light irradiation with a 405 nm LED diode (Thorlabs M405L4, 20 mW/cm^2), and tracked by UV–vis absorption. The dark stability was also tracked for **2** ($2 \times 10^{-5}\text{ M}$) in PBS and white cell media. The photostability

experiment for **2** ($2 \times 10^{-5}\text{ M}$, 70:30 (v/v) DMSO- d_6 /D $_2$ O) was tracked by ^1H -NMR in a Bruker 500 MHz spectrometer.

Cyclic voltammetry

CV experiments were performed using an Autolab 100 potentiostat, with a glassy carbon working electrode, a platinum wire counter electrode and Ag/AgCl (0.1 mol dm^{-3}) reference electrode. Solutions of the complexes 10^{-3} M were prepared in CH_2Cl_2 using 0.4 M of $[\text{NBu}_4][\text{PF}_6]$ as the supporting electrolyte and were bubbled for at least 15 min with N_2 to remove any traces of oxygen prior to run the measurements. The last run was recorded with Fc to reference according to the Fc/Fc $^+$ couple.

X-ray diffraction

Crystal structures were solved in a Bruker AXS Venture apparatus. Single crystals of **1** suitable for diffraction were obtained from the slow evaporation of a dichloromethane solution. Crystals were mounted in fomblin oil on a MiTi-Gen microloop and cooled in a stream of cold N_2 . The structure has been deposited in the CCDC 2284133.

Singlet oxygen quantum yield

The quantum efficiency of singlet oxygen ($^1\text{O}_2$) production was determined by time-resolved near-IR emission at 1270 nm upon laser excitation. An optically matched solution of perinaphthenone was used as the reference with known quantum yield ($\Phi_s = 1.0$ in CH_3CN [41]). The kinetic traces were recorded at a set of different energies of 355-nm, 12-ns output of a LOTIS TII Nd:Yag laser (25, 50, 75 and 100 μJ) for both the sample and perinaphthenone solutions. The amplitude of the emission signal at time = 0 was plotted as a function of excitation energy, and the yield determined by comparing the slopes of such linear dependencies for the sample studied vs. that of perinaphthenone.

Transient absorption

Femtosecond Transient Absorption (TA) spectroscopy was performed at the Lord Porter Laser Laboratory, University of Sheffield. A Ti:Sapphire regenerative amplifier (Spitfire ACE PA-40, Spectra-Physics) provided 800 nm pulses (40 fs FWHM, 10 kHz, 1.2 mJ). 400 nm pulses for excitation were generated by doubling a portion of the 800 nm output in a β -barium borate crystal within a commercially available doubler/tripler (TimePlate, Photop Technologies). White light supercontinuum probe pulses in the range 340–790 nm were generated with a CaF_2 crystal (continuously displaced to avoid damage). Detection was achieved using a commercial transient absorption spectrometer (Helios, Ultrafast

Systems) using a 2048-pixel CMOS sensor for UV–Vis detection. The relative polarisation of the pump and probe was set to magic angle (54.7°) for anisotropy-free measurements. Samples were held in 2 mm path length quartz cells in CH_2Cl_2 (absorption of 0.4 at the excitation wavelength) and were stirred during experiments.

Cell line and culture conditions

EJ cells were obtained from ATTC. The cells were maintained in DMEM (Dulbecco's modified Eagle's medium, Gibco) with 10% of FBS (foetal bovine serum). Cells were cultured in a humidified incubator at 37°C under 5% CO_2 . Cells were regularly tested for mycoplasma.

Cytotoxicity and phototoxicity

Cytotoxicity and phototoxicity were determined by clonogenic survival assays. For dark toxicity, cells were plated into 6-well plates (200 or 400 cells/well) and allowed to grow overnight. The drugs (stock solutions in DMSO) were added alongside DMSO alone as a vehicle control. The DMSO concentration in the final solutions never exceed 2%. The cells were then incubated for 2 h before removal and replacement of the media. After 7 days, colonies were stained with methylene blue solution (3%, 70:30 ethanol/water) and the colonies counted with a colony counter. For phototoxicity, cells were plated into 12-well plates and allowed to grow overnight. Cells were exposed to drug and incubated for 2 h before being trypsonized and resuspended in phenol-red free media. The cell suspensions were transferred to soda-lime glass vials and preserved on ice. Dark control suspensions were also prepared for each condition. The solutions were irradiated for 3 min with a blue LED diode (Thorlabs, $\lambda = 405$ or 455 nm, 20 mW/cm²). Each condition was then replated into 6 well dishes at 300 and 600 cells and left for 7 days to form colonies which were then stained and counted. All the experiments were performed in triplicates (at least) and on three separate occasions.

Dose dependent cell uptake studies

Cells were plated onto glass coverslips in 6 well dishes and incubated overnight. Cells were incubated with $10\ \mu\text{M}$ and $30\ \mu\text{M}$ **1** for 2 h or treated with DMSO control (final DMSO amount 0.2%). Following this, the coverslips were washed with PBS (3×1 mL/well) and cells fixed with PFA solution (3%, PBS, 1 mL/well, 10 min, RT). Coverslips were again washed (PBS, 3×1 mL/well) before being mounted onto glass slides (ProLong™ Antifade Gold Mountant, 1 drop).

Imaging

Cell imaging was performed using a Nikon Widefield Live Cell Dual Cam microscope on fixed and mounted coverslips. Excitation was performed using a SpectraX LED source and the emission was passed through a relevant filter before image capture. For each condition, a brightfield and fluorescence image was taken, and a merge presented. Each image was captured as a 3D z-stack before being deconvoluted using a Richardson-Lucy algorithm to reduce out of focus fluorescence.

Co-localization in mitochondria

EJ cells were plated onto sterilised glass coverslips in a 6-well dish and incubated overnight. Following this, cells were exposed to **1** ($30\ \mu\text{M}$, 2 h) and then fixed in PFA (4% in PBS, 10 min). Cells were then permeabilised with Triton X-100 (0.2% in PBS, 10 min), blocked with BSA (2% in PBS, 1 h) before being exposed to a monoclonal antibody to a mitochondria exclusive protein, cytochrome c oxidase (1:200 in PBS, overnight 4°C , Abcam, ab133504). The next day, cells were exposed to Alexa Fluor™ 488 anti-rabbit secondary antibody (1:500 in PBS, 1 h) before being mounted onto glass slides (Prolong Gold Antifade). Z-stacked images were then captured with the separate emissions of **1** (red) and anti-cytochrome c oxidase (green) collected per stack. Images were deconvoluted using the Lucy-Richardson algorithm and rendered into a single frame. Pixel overlap and hence co-localisation between the merged emission images of **1** and anti-cytochrome c oxidase were quantified using the Coloc2 program in the image processing software ImageJ.

Conclusions

We have reported two Ir(III) photosensitizers bearing two cyclometallating ligands, thienyl-pyridine (thpy), and either two mono- or one bidentate imidazole-based ligands, namely 2-(2'-benzothiazolyl)-benzimidazole in **1** and imidazole in **2**. As expected, **1** is photostable, whilst **2** is not. Both complexes absorb visible light, are brightly emissive, and generate singlet oxygen upon irradiation with high yields (40% for **1** and 82% for **2**). The lowest excited state in **2**, without the diimine ligand, is of a pure ³IL (intra-thienyl-pyridine) nature, as is indicated by its long lifetime (2 microseconds in deoxygenated solution), and clear vibrational progression in the emission spectrum. However, complex **2** was found to be toxic in the dark, potentially due to dissociation of imidazole ligand. It is thus not suitable for PDT but could form a basis for development of a future drug working through release of imidazole, joining a large family of agents based on imidazole scaffolds [46].

Complex **1** carries a bidentate, diimine ligand, and possesses a manifold of lowest excited states of a mixed $^3\text{IL}/^3\text{MLCT}$ origin, as is evidenced by the shape of its emission spectrum. **1** was shown to be a good PS agent, non-toxic in dark conditions, and with a $\text{PI} > 250$ after irradiation at 405 nm and $\text{PI} > 150$ at 455 nm, after short irradiation time and at low fluences. Overall, this study contributes to the development of metal complexes for therapies, and offers a new photosensitizer, **1**, which works under visible light, in a set of cancer-related cell lines, at low fluences and low dose of light.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00775-023-02031-z>.

Acknowledgements This research was supported by University of Sheffield, Rosetrees Trust grant number M698 Wellcome Trust grant WT093134AIA and MRC SHIMA award MR/K015753/L. M.M. acknowledges the support from the Fundación Alfonso Martín Escudero for her postdoctoral grant. JAW is grateful for the Leverhulme Trust senior research fellowship. We thank the EPSRC for funding for the Lord Porter Laser Laboratory. We thank Dr. Craig Robertson for the refinement of crystal data and Dr Darren Robinson, Wolfson Light Microscopy Facility for training and advice on imaging.

Author contributions MM and CJ carried out the majority of experimental synthetic and spectroscopic work, MM and CJ performed cellular uptake and imaging studies, JDS performed and analysed transient absorption data. Data analysis by MM, CJ, HEB and JAW. Principal investigators, study design and supervision by HEB and JAW. The manuscript was written by all authors.

Data availability Crystallographic data for the structure reported in this article has been deposited at the Cambridge Crystallographic Data Centre, under deposition number CCDC 2284133 (1). Copies of the data can be obtained free of charge via <https://www.ccdc.cam.ac.uk/structures/>. The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary Information files. Should any raw data files be needed in another format they are available from the corresponding authors upon reasonable request.

Declarations

Conflict of interest The authors declare no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. WHO Top 10 causes of death. <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>. Accessed 19 July 2023
2. Piccart MJ, Lamb H, Vermorken JB (2001) Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. *Ann Oncol* 12:1195–1203
3. Zhang L, Zhao Z, Wang P et al (2021) Long-term improvement on photoaging after ALA photodynamic therapy for actinic keratosis: a retrospective study. *Photodiagnosis Photodyn Ther* 33:102181. <https://doi.org/10.1016/j.pdpdt.2021.102181>
4. Morton CA, Braathen LR (2018) Daylight photodynamic therapy for actinic keratoses. *Am J Clin Dermatol* 19:647–656. <https://doi.org/10.1007/s40257-018-0360-y>
5. Babilas P, Schreml S, Landthaler M, Szeimies R-M (2010) Photodynamic therapy in dermatology: state-of-the-art. *Photodermatol Photoimmunol Photomed* 26:118–132. <https://doi.org/10.1111/j.1600-0781.2010.00507.x>
6. Wormald R, Evans J, Smeeth L, Henshaw K (2005) Photodynamic therapy for neovascular age-related macular degeneration. In: Wormald R (ed) *Cochrane database of systematic reviews*. Wiley, Chichester, pp 81–95
7. Foroulis CN, Thorpe JAC (2006) Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer. *Eur J Cardiothorac Surg* 29:30–34. <https://doi.org/10.1016/j.ejcts.2005.10.033>
8. Fuchs SM, Fluhr JW, Bankova L, et al (2004) Photodynamic therapy (PDT) and waterfiltered infrared A (wIRA) in patients with recalcitrant common hand and foot warts. *Ger Med Sci* 2:Doc08
9. Meisel P, Kocher T (2005) Photodynamic therapy for periodontal diseases: state of the art. *J Photochem Photobiol B* 79:159–170. <https://doi.org/10.1016/j.jphotobiol.2004.11.023>
10. Hamblin MR, Hasan T (2004) Photodynamic therapy: a new antimicrobial approach to infectious disease? *Photochem Photobiol Sci* 3:436–450. <https://doi.org/10.1039/b311900a>
11. Karges J (2022) Clinical development of metal complexes as photosensitizers for photodynamic therapy of cancer. *Angew Chem Int Ed* 61:e202112236. <https://doi.org/10.1002/anie.202112236>
12. Monro S, Colón KL, Yin H et al (2019) Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD1433. *Chem Rev* 119:797–828. <https://doi.org/10.1021/acs.chemrev.8b00211>
13. Fong J, Kasimova K, Arenas Y et al (2015) A novel class of ruthenium-based photosensitizers effectively kills in vitro cancer cells and in vivo tumors. *Photochem Photobiol Sci* 14:2014–2023. <https://doi.org/10.1039/C4PP00438H>
14. Inc. T TLD-1433 Clinical Trial. <https://clinicaltrials.gov/ct2/show/NCT03945162>. Accessed 19 July 2023.
15. Wu Y, Wu J, Wong W-Y (2021) A new near-infrared phosphorescent iridium(III) complex conjugated to a xanthene dye for mitochondria-targeted photodynamic therapy. *Biomater Sci* 9:4843–4853. <https://doi.org/10.1039/D1BM00128K>
16. Novohradsky V, Rovira A, Hally C et al (2019) Towards novel photodynamic anticancer agents generating superoxide anion radicals: a Cyclometalated Ir III complex conjugated to a far-red emitting Coumarin. *Angew Chem Int Ed* 58:6311–6315. <https://doi.org/10.1002/anie.201901268>
17. Liu J, Jin C, Yuan B et al (2017) Enhanced cancer therapy by the marriage of metabolic alteration and mitochondrial-targeted photodynamic therapy using cyclometalated Ir(III) complexes. *Chem Commun* 53:9878–9881. <https://doi.org/10.1039/C7CC05518H>
18. Martínez-Alonso M, Busto N, Aguirre LD et al (2018) Strong influence of the ancillary ligand over the photodynamic anticancer

- properties of neutral biscyclometalated Ir^{III} complexes bearing 2-benzazole-phenolates. *Chem Eur J* 24:17523–17537. <https://doi.org/10.1002/chem.201803784>
19. Huang H, Banerjee S, Sadler PJ (2018) Recent advances in the design of targeted Iridium(III) photosensitizers for photodynamic therapy. *ChemBioChem* 19:1574–1589. <https://doi.org/10.1002/cbic.201800182>
 20. McKenzie LK, Sazanovich IV, Baggaley E et al (2017) Metal complexes for two-photon photodynamic therapy: a cyclometalated iridium complex induces two-photon photosensitization of cancer cells under near-IR light. *Chem Eur J* 23:234–238. <https://doi.org/10.1002/chem.201604792>
 21. Wu N, Cao J, Wu X et al (2017) Iridium(III) complexes with five-membered heterocyclic ligands for combined photodynamic therapy and photoactivated chemotherapy. *Dalton Trans* 46:13482–13491. <https://doi.org/10.1039/C7DT02477K>
 22. Yang J, Shi Z, Wang W et al (2022) Phosphorescent platinum (II), iridium (III) and ruthenium (II) complexes with monodentate imidazole ligands respond to the reductive microenvironment of living cells. *J Inorg Biochem* 231:111803. <https://doi.org/10.1016/j.jinorgbio.2022.111803>
 23. He L, Li Y, Tan C-P et al (2015) Cyclometalated iridium(III) complexes as lysosome-targeted photodynamic anticancer and real-time tracking agents. *Chem Sci* 6:5409–5418. <https://doi.org/10.1039/C5SC01955A>
 24. Mandal S, Poria DK, Ghosh R et al (2014) Development of a cyclometalated iridium complex with specific intramolecular hydrogen-bonding that acts as a fluorescent marker for the endoplasmic reticulum and causes photoinduced cell death. *Dalton Trans* 43:17463–17474. <https://doi.org/10.1039/C4DT00845F>
 25. Wang F-X, Chen M-H, Lin Y-N et al (2017) Dual functions of cyclometalated iridium(III) complexes: anti-metastasis and lysosome-damaged photodynamic therapy. *ACS Appl Mater Interfaces* 9:42471–42481. <https://doi.org/10.1021/acsami.7b10258>
 26. Ye R-R, Tan C-P, Ji L-N, Mao Z-W (2016) Coumarin-appended phosphorescent cyclometalated iridium(III) complexes as mitochondria-targeted theranostic anticancer agents. *Dalton Trans* 45:13042–13051. <https://doi.org/10.1039/C6DT00601A>
 27. Yuan Y-J, Yu Z-T, Gao H-L et al (2013) Tricyclometalated iridium complexes as highly stable photosensitizers for light-induced hydrogen evolution. *Chem Eur J* 19:6340–6349. <https://doi.org/10.1002/chem.201300146>
 28. Peng W, Hegazy AM, Jiang N et al (2020) Identification of two mitochondrial-targeting cyclometalated iridium(III) complexes as potent anti-glioma stem cells agents. *J Inorg Biochem* 203:110909. <https://doi.org/10.1016/j.jinorgbio.2019.110909>
 29. Chen M-H, Zheng Y, Cai X-J et al (2019) Inhibition of autophagic flux by cyclometalated iridium(III) complexes through anion transportation. *Chem Sci* 10:3315–3323. <https://doi.org/10.1039/C8SC04520H>
 30. Nonoyama M (1974) Benzo[h]quinolin-10-yl-N Iridium(III) complexes. *Bull Chem Soc Jpn* 47:767–768
 31. Baig MF, Shaik SP, Nayak VL et al (2017) Iodine-catalyzed C sp³-H functionalization of methylarenes: one-pot synthesis and cytotoxic evaluation of heteroarenyl-benzimidazoles and benzothiazole. *Bioorg Med Chem Lett* 27:4039–4043. <https://doi.org/10.1016/j.bmcl.2017.07.051>
 32. Jeffrey GA (1997) An introduction to hydrogen bonding. Oxford University Press, Oxford
 33. Bünzli AM, Bolink HJ, Constable EC et al (2014) Thienylpyridine-based cyclometalated iridium(III) complexes and their use in solid state light-emitting electrochemical cells. *Dalton Trans* 43:738–750. <https://doi.org/10.1039/C3DT52622D>
 34. Chen M, Wang F, Cao J et al (2017) Light-up mitophagy in live cells with dual-functional theranostic phosphorescent iridium(III) complexes. *ACS Appl Mater Interfaces* 9:13304–13314. <https://doi.org/10.1021/acsami.7b01735>
 35. Lamansky S, Djurovich P, Murphy D et al (2001) Synthesis and characterization of phosphorescent cyclometalated iridium complexes. *Inorg Chem* 40:1704–1711. <https://doi.org/10.1021/ic0008969>
 36. Pérez-Arnaiz C, Acuña MI, Busto N et al (2018) Thiabendazole-based Rh(III) and Ir(III) biscyclometalated complexes with mitochondria-targeted anticancer activity and metal-sensitive photodynamic activity. *Eur J Med Chem* 157:279–293. <https://doi.org/10.1016/j.ejmech.2018.07.065>
 37. Martínez-Alonso M, Cerdá J, Momblona C et al (2017) Highly stable and efficient light-emitting electrochemical cells based on cationic iridium complexes bearing arylazole ancillary ligands. *Inorg Chem* 56:10298–10310. <https://doi.org/10.1021/acs.inorgchem.7b01167>
 38. Caspar JV, Meyer TJ (1983) Photochemistry of tris(2,2'-bipyridine)ruthenium(2+) ion ([Ru(bpy)₃]²⁺). Solvent effects. *J Am Chem Soc* 105:5583–5590. <https://doi.org/10.1021/ja00355a009>
 39. Murphy L, Congreve A, Pålsson L-O, Williams JAG (2010) The time domain in co-stained cell imaging: time-resolved emission imaging microscopy using a protonatable luminescent iridium complex. *Chem Commun* 46:8743–8745. <https://doi.org/10.1039/c0cc03705b>
 40. Perrin HH (1972) Dissociation constants of organic bases in aqueous solution: supplement 1972. International Union of Pure and Applied Chemistry, London
 41. Schmidt R, Tanielian C, Dunsbach R, Wolff C (1994) Phenalenone, a universal reference compound for the determination of quantum yields of singlet oxygen O₂(¹Δ_g) sensitization. *J Photochem Photobiol A Chem* 79:11–17. [https://doi.org/10.1016/1010-6030\(93\)03746-4](https://doi.org/10.1016/1010-6030(93)03746-4)
 42. Ouyang M, Zeng L, Qiu K et al (2017) Cyclometalated Ir III complexes as mitochondria-targeted photodynamic anticancer agents. *Eur J Inorg Chem* 2017:1764–1771. <https://doi.org/10.1002/ejic.201601129>
 43. You Y, Cho EJ, Kwon H et al (2016) A singlet oxygen photosensitizer enables photoluminescent monitoring of singlet oxygen doses. *Chem Commun* 52:780–783. <https://doi.org/10.1039/C5CC08411C>
 44. Guerra F, Arbini AA, Moro L (2017) Mitochondria and cancer chemoresistance. *Biochimica et Biophysica Acta (BBA)—Bioenergetics* 1858:686–699. <https://doi.org/10.1016/j.bbabi.2017.01.012>
 45. Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondria for cancer therapy. *Nat Rev Drug Discov* 9:447–464. <https://doi.org/10.1038/nrd3137>
 46. Zhang L, Peng X-M, Damu GLV et al (2014) Comprehensive review in current developments of imidazole-based medicinal chemistry. *Med Res Rev* 34:340–437. <https://doi.org/10.1002/med.21290>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.